Sitemap - 2024 - On The Pen
More Generic GLP-1 Options Hit The Market!
On The Pen: The Weekly Dose 12.17.24
An Inflatable Stomach Balloon for Weight Loss
A GLP-1 Monopoly In The Making: Biden Admin Fails to Act, Novo Acquires Catalent
OFA Representation in Compound Tirzepatide Case Sits Down with OTP
CagriSema Delay? Novo Catalent Update
American Diabetes Association on the Wrong Side of Compounded GLP-1 Meds
Like Ozempic, But You Only Take It Once! Fractyl Health CEO Dr. Harith Rajagopalan
Retatrutide Cagrisema & Obesity Medicine Future With Dr. Michael Albert
Medicare to Cover Zepbound and Wegovy?
Compound Tirzepatide Future + @FitFlavorFun : OTP EPS 91
On The Pen: The Weekly Dose 11.19.24
CNN Special: Is Ozempic For You? With Dr. Gupta OTP REVIEW
Dr Spencer Nadolsky: Docs Who Lift Pod | OTP Eps 90
Novo Nordisk's War on Compound Semaglutide, Maritide Has Some Negative News
Viking Therapeutics and AstraZeneca Steal The Show at Obesity Week!
Lilly Earnings Call Analysis: Why Zepbound Missed Earnings
New Zepbound Savings Card, GLP-1 Accessibility Landscape Evolves
Tirzepatide Lawsuits Filed By Lilly, Catalent Reframing Novo Merger
Compounded Zepbound Legal Battle Landscape: Legal Expert Weighs In
Compounded Zepbound Uncertainty + Leveraging GLP-1 To Improve Labor Shortages
Heartbreaking Zepbound Story | OTP Eps 85
Tirzepatide Lawsuits + Ozempic Patent Victory
Megadosing Zepbound and Mounjaro With Dr. Daniel Rosen
Ozempic and Zepbound Supply Impacted by Port Worker Strike!
Amy Kane @AmyInHalf Discusses Dramatic Mounjaro Transformation
On The Pen: The Weekly Dose 9.24.24
Eli Lilly Compound Tirzepatide Letters + Retatrutide Trial Guest!
BCBS Demanding Refunds From Ozempic Prescribers? | The Weekly Dose 9.17.24
On The Pen: The Weekly Dose 9.10.24
Dr. Spencer Nadolsky On Compound Tirzepatide After Leaving Weight Watchers
Ozempic Shortages Extended | The Weekly Dose 9.3.24
Zepbound Savings Card & Zepbound Vials Discussion With The Downsized
Massive Zepbound Vials News 8.27.24
On The Pen: The Weekly Dose 8.20.24
On The Pen: The Weekly Dose 8.13.24
On The Pen: The Weekly Dose 8.6.24
On The Pen: The Weekly Dose 7.30.24
On The Pen: The Weekly Dose 7.23.24
On The Pen: The Weekly Dose 7.16.24
Amylin and the future of obesity medicine with Dr. Beverly Tchang
On The Pen: The Weekly Dose 7.9.24
On The Pen: The Weekly Dose 7.2.24
On The Pen: The Weekly Dose 6.25.24
On The Pen: The Weekly Dose 6.18.24
On The Pen: The Weekly Dose 6.11.24
On The Pen: The Weekly Dose 6.4.24
OTP EPS 68: Ro CEO Zach Reitano Talks GLP-1 Supply Tracker
On The Pen: The Weekly Dose 5.28.24
On The Pen Live Eps 67: Survodutide Trial Participant Tells All!
On The Pen: The Weekly Dose 5.21.24
On The Pen: The Weekly Dose 5.14.24
Threats to Lilly's Zepbound & Mounjaro Printing Press
On The Pen: The Weekly Dose 5.7.24
Lilly Earnings Call: Zepbound and Mounjaro Updates
On The Pen: The Weekly Dose 4/30/24
On The Pen: The Weekly Dose 4/23/24
Zepbound Vials: The Business Case
On The Pen: The Weekly Dose 4/16/24
On The Pen: The Weekly Dose 4.9.24
Zepbound Single Dose Vials Approved!
On The Pen: The Weekly Dose 3/26/24
On The Pen: The Weekly Dose 3/19/24
Novo Nordisk Pipeline Obesity Medicines Announced
On The Pen: The Weekly Dose 3/5/24
Mounjaro to Zepbound and Beyond with Dr. Albert
On The Pen: The Weekly Dose 2/27/24
On The Pen: The Weekly Dose 2/20/24
Zepbound Mounjaro Ozempic News: 2.13.24
Q4 Eli Lilly Earnings Call Recap
On The Pen: The Weekly Dose 2.6.24
Q4 Novo Nordisk Earnings Call Recap
On The Pen: The Weekly Dose 1.30.24
On The Pen: The Weekly Dose 1.23.24